Antagonists of the transcription factor c-maf Short Form for the treatment of glaucoma

摘要

The regulation has been identified in Rise of the version of the short form of the transcription factor c-maf in trabecular meshwork cells treated with steroids and treated with factorTransforming Growth B 2,And is present at high levels in cells of the trabecular meshwork glaucomatosas Unlike in the tissue of normal and glaucomatous optic nerve Head and not in the normal.The expression of the transcription factor of the short form of c-maf in these Conditions or effector role indicates a causal factor in the Pathogenesis of Primary open-angle glaucoma and the GLAucoma induced by steroids.It causes the antagonism of the expression and activity of Transcription Factor of the short form of c-maf in the trabecular meshwork or other ocular Tissue to inhibit or alleviate the pathogenesisThe glaucoma. Among the antagonists are inhibitors of Cyclin Dependent Kinase 2.Purine analogues, such as purvalanol and Inhibitors of the cyclin kinase 2 Slope without purine base.Claim 1: a composition for the treatment of primary Open angle glaucoma or glaucoma induced by steroids.Composition comprising an antagonist of the transcription factor of the short form of c-maf and acceptable vehicle.Claim 2: a composition according to claim 1,In which the antagonist of the transcription factor of the short form of c-maf comprises a purine Analogue with Inhibitory activity of Cyclin Dependent Kinase Cdk2.